Zobrazeno 1 - 10
of 175
pro vyhledávání: '"CARLO MESSINA"'
Autor:
Sara Elena Rebuzzi, Giuseppe Fornarini, Alessio Signori, Sebastiano Buti, Giuseppe Procopio, Ugo De Giorgi, Sandro Pignata, Emanuele Naglieri, Marco Maruzzo, Giuseppe Luigi Banna, Pasquale Rescigno, Carlo Messina, Alvise Mattana, Umberto Basso, Davide Bimbatti
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-5 (2024)
Abstract Background Nowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC). Immuno-combinations are the standard first-line therapy in all mRCC patients regardless of the Internati
Externí odkaz:
https://doaj.org/article/07fb9d1891ed48f8877a4dc092e2bedf
Autor:
Francesco Tovoli, Vincenzo Dadduzio, Stefania De Lorenzo, Lorenza Rimassa, Gianluca Masi, Massimo Iavarone, Fabio Marra, Ingrid Garajova, Maria Pia Brizzi, Bruno Daniele, Franco Trevisani, Carlo Messina, Francesco Di Clemente, Sara Pini, Giuseppe Cabibbo, Alessandro Granito, Mario Domenico Rizzato, Vittorina Zagonel, Giovanni Brandi, Tiziana Pressiani, Piera Federico, Caterina Vivaldi, Irene Bergna, Claudia Campani, Fabio Piscaglia
Publikováno v:
Liver Cancer, Vol 10, Iss 4, Pp 370-379 (2021)
Introduction: Cabozantinib has been approved by the European Medicine Agency (EMA) for hepatocellular carcinoma (HCC) previously treated with sorafenib. Cabozantinib is also being tested in combination with immune checkpoint inhibitors in the frontli
Externí odkaz:
https://doaj.org/article/35465bb2f20d44ce85e4f6039cf0e079
Autor:
Valeria Merz, Domenico Mangiameli, Camilla Zecchetto, Alberto Quinzii, Silvia Pietrobono, Carlo Messina, Simona Casalino, Marina Gaule, Camilla Pesoni, Pasquale Vitale, Chiara Trentin, Michela Frisinghelli, Orazio Caffo, Davide Melisi
Publikováno v:
Frontiers in Surgery, Vol 9 (2022)
The mainstay treatment for patients with immediate resectable pancreatic cancer remains upfront surgery, which represents the only potentially curative strategy. Nevertheless, the majority of patients surgically resected for pancreatic cancer experie
Externí odkaz:
https://doaj.org/article/a3bc1019d4774d3d9b135653201445c7
Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis
Autor:
Carlo Cattrini, Carlo Messina, Chiara Airoldi, Sebastiano Buti, Giandomenico Roviello, Alessia Mennitto, Orazio Caffo, Alessandra Gennari, Melissa Bersanelli
Publikováno v:
Therapeutic Advances in Urology, Vol 13 (2021)
Background: In recent years, new therapeutic combinations based on immunotherapy provided significant benefits as a first-line treatment for patients with advanced renal cell carcinoma (mRCC). Objective: This work aims to address the lack of head-to-
Externí odkaz:
https://doaj.org/article/7f88a95dc6f34403b9c22622b09df00e
Autor:
Lorenzo Lazzari, Annalisa Ruggeri, Maria Teresa Lupo Stanghellini, Sara Mastaglio, Carlo Messina, Fabio Giglio, Alessandro Lorusso, Tommaso Perini, Simona Piemontese, Magda Marcatti, Francesca Lorentino, Elisabetta Xue, Daniela Clerici, Consuelo Corti, Massimo Bernardi, Andrea Assanelli, Raffaella Greco, Fabio Ciceri, Jacopo Peccatori
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
IntroductionReducing toxicities while preserving efficacy in allogeneic stem cell transplant (allo-HCT) remains a particularly challenging problem. Different strategies to enhance the antitumor activity without increasing early and late adverse toxic
Externí odkaz:
https://doaj.org/article/5b0b5fc21f444531b9743fc7ce584fa3
Autor:
Alessandro Rizzo, Massimiliano Salati, Giorgio Frega, Valeria Merz, Francesco Caputo, Alessandro Di Federico, Andrea Palloni, Riccardo Carloni, Angela Dalia Ricci, Gennaro Gadaleta-Caldarola, Carlo Messina, Andrea Spallanzani, Fabio Gelsomino, Stefania Benatti, Gabriele Luppi, Davide Melisi, Massimo Dominici, Giovanni Brandi
Publikováno v:
Medicina, Vol 58, Iss 11, p 1543 (2022)
Objectives: The ABC-06 and the NIFTY trials recently established the role of second-line chemotherapy (2L) in patients with advanced biliary tract cancer (BTC). Our real-world study aimed to explore 2L in BTC patients aged ≥ 70 years old and to com
Externí odkaz:
https://doaj.org/article/21706d9457d3468996d4a95259512694
Autor:
Giandomenico Roviello, Sebastiano Buti, Carlo Cattrini, Alessia Mennitto, Carlo Messina, Chiara Airoldi, Gianmarco Vannini, Melissa Bersanelli
Publikováno v:
Therapeutic Advances in Urology, Vol 13 (2021)
Externí odkaz:
https://doaj.org/article/188809f92a4b473e87c21baf2b6567bc
Autor:
Fabio Serpenti, Francesca Lorentino, Sarah Marktel, Raffaella Milani, Carlo Messina, Raffaella Greco, Stefania Girlanda, Daniela Clerici, Fabio Giglio, Carmine Liberatore, Francesca Farina, Sara Mastaglio, Simona Piemontese, Elena Guggiari, Francesca Lunghi, Magda Marcatti, Matteo G. Carrabba, Massimo Bernardi, Chiara Bonini, Andrea Assanelli, Consuelo Corti, Jacopo Peccatori, Fabio Ciceri, Maria Teresa Lupo-Stanghellini
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
IntroductionAllogeneic stem cell transplantation survivors are at a relevant risk of developing chronic GvHD (cGvHD), which importantly affects quality of life and increases morbidity and mortality. Early identification of patients at risk of cGvHD-r
Externí odkaz:
https://doaj.org/article/caf0c238642b4591a56e0d0b9525a3e1
Autor:
Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, Marco Maruzzo, Ugo De Giorgi, Paolo Pedrazzoli, Andrea Sbrana, Paolo Andrea Zucali, Cristina Masini, Emanuele Naglieri, Giuseppe Procopio, Sara Merler, Laura Tomasello, Lucia Fratino, Cinzia Baldessari, Riccardo Ricotta, Stefano Panni, Veronica Mollica, Mariella Sorarù, Matteo Santoni, Alessio Cortellini, Veronica Prati, Hector Josè Soto Parra, Marco Stellato, Francesco Atzori, Sandro Pignata, Carlo Messina, Marco Messina, Franco Morelli, Giuseppe Prati, Franco Nolè, Francesca Vignani, Alessia Cavo, Giandomenico Roviello, Francesco Pierantoni, Chiara Casadei, Melissa Bersanelli, Silvia Chiellino, Federico Paolieri, Matteo Perrino, Matteo Brunelli, Roberto Iacovelli, Camillo Porta, Sebastiano Buti, Giuseppe Fornarini
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Despite the survival advantage, not all metastatic renal cell carcinoma (mRCC) patients achieve a long-term benefit from immunotherapy. Moreover, the identification of prognostic biomarkers is still an unmet clinical need. Methods: This m
Externí odkaz:
https://doaj.org/article/b7fbd6a0e95e4fbc8e3f9aaff8b8f0d2
Publikováno v:
Frontiers in Public Health, Vol 8 (2020)
Background: The COVID-19 outbreak rapidly became a public health emergency affecting particularly the frail category as cancer patients. This led oncologists to radical changes in patient management, facing the unprecedent issue whether treatments in
Externí odkaz:
https://doaj.org/article/ec742b2f074246d6b2f1ad0a3ae98828